Experience real-time quotes, in-depth charts, and analyst ratings

MARKET

ROIV

Roivant Sciences

NASDAQ

10.87

+0.03

+0.23%

Opening 13:15 04/16 EDT

OPEN

10.77

PREV CLOSE

10.84

HIGH

10.88

LOW

10.64

VOLUME

2.02M

TURNOVER

52 WEEK HIGH

13.24

52 WEEK LOW

7.01

MARKET CAP

8.76B

P/E (TTM)

2.067

Weekly Report: what happened at ROIV last week (0408-0412)?

Weekly Report · 1d ago

Arbutus Biopharma: The Markman Win Is A Good Milestone But Uncertainty Remains

Arbutus Biopharma and Roivant won a crucial claims construction ruling in their patent infringement lawsuit against Moderna. The ruling opens the way for a potential win against the pharma giant, but uncertainties remain regarding the lawsuit and Arbutus' pipeline. The potential litigation payout could be significant, but the company's expensive pipeline development and cash burn rate are concerns.

Seeking Alpha · 6d ago

Weekly Report: what happened at ROIV last week (0401-0405)?

Weekly Report · 04/08 12:21

Analysts Anticipate FXH Will Reach $123

NASDAQ · 04/08 10:38

UPDATE 1-Moderna shares fall after judge sides with Arbutus in patent fight

Moderna shares fall after judge sides with Arbutus in patent fight. Shares of Moderna MRNA.O fell 4% in afternoon trading. A U.S. Judge interpreted parts of the patents in ways that strengthened Ar butus' case. The lawsuit is related to Moderna's blockbuster COVID-19 vaccines.

Reuters · 04/03 18:48

BUZZ-Moderna slides after judge sides with Arbutus in patent fight

U.S. Judge sides with Arbutus in patent infringement lawsuit related to MRNA's blockbuster vaccines. Shares of Moderna slide 3.5% to $100 after the news. MRNA is a joint venture of MRNA and Roivant Sciences. Ar butus shares up 12.1% in after-hours trading.

Reuters · 04/03 18:15

Arbutus Biopharma jumps after patent victory in fight with Moderna

Seeking Alpha · 04/03 16:27

Roivant Sciences Price Target Raised to $18.00/Share From $16.00 by Goldman Sachs

Dow Jones · 04/03 15:28

About ROIV

Roivant Sciences Ltd. is a commercial-stage biopharmaceutical company that seeks to improve the lives of patients by accelerating the development and commercialization of medicines that matter. The Company’s pipeline is focused on inflammation and immunology and includes VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; batoclimab and IMVT-1402, fully human monoclonal antibodies targeting the neonatal Fc receptor (FcRn) in development across several IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody in development for ulcerative colitis and Crohn’s disease, in addition to various other therapies in various stages of clinical development. The Company advances its pipeline by creating nimble subsidiaries or Vants to develop and commercialize its medicines and technologies. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.

Webull offers Roivant Sciences Ltd stock information, including NASDAQ: ROIV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ROIV stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ROIV stock methods without spending real money on the virtual paper trading platform.